SCHEMBL6595771

SCHEMBL6595771

CCN1CCN([S+]([O-])c2ccc(Br)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DUSP3 P51452 3/20 0.49
PTPN5 P54829 3/20 0.49
PTPN11 Q06124 3/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
GPR183 P32249 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
HTT P42858 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 4/20 0.37
NPSR1 Q6W5P4 1/20 0.37
GAA P10253 2/20 0.36
RAD52 P43351 2/20 0.36
APAF1 O14727 1/20 0.36
MITF O75030 1/20 0.36
CHRNA7 P36544 1/20 0.36
GFER P55789 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18828601 0.81 ALDH1A1 (0.44) DUSP3PTPN5PTPN11CYP1A2CYP3A4
SCHEMBL22340249 0.78 HPGD (0.37) L3MBTL1SMN1; SMN2ALDH1A1HPGD
SCHEMBL22643223 0.77 HPGD (0.36) L3MBTL1SMN1; SMN2ALDH1A1MAPTKDM4E
SCHEMBL3773093 0.72 DPP4 (0.34)
SCHEMBL20310914 0.70 KDM4E (0.34) SMN1; SMN2KDM4E
SCHEMBL5257237 0.69 ALDH1A1 (0.69) DUSP3PTPN5PTPN11CYP1A2CYP3A4
SCHEMBL578273 0.69 GAA (0.67) DUSP3PTPN5PTPN11CYP1A2CYP3A4
SCHEMBL21613823 0.68 DHCR7 (0.39) CYP2D6L3MBTL1HTTGAATP53
SCHEMBL17402954 0.68 TSHR (0.33) MAPT
SCHEMBL3783625 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1414801-A1 ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 AstraZeneca AB (SE) 2004-05-06 EP disclosed
WO-2003004472-A1 ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 ASTRAZENECA AB (SE) 2003-01-16 WO disclosed